- Home
- ENX vs CRVS Comparison
ENX vs CRVS Comparison
Compare ENX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- CRVS
- Stock Information
- Founded
- ENX 2002
- CRVS 2014
- Country
- ENX United States
- CRVS United States
- Employees
- ENX N/A
- CRVS N/A
- Industry
- ENX Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- CRVS Health Care
- Exchange
- ENX Nasdaq
- CRVS Nasdaq
- Market Cap
- ENX 178.4M
- CRVS 161.4M
- IPO Year
- ENX N/A
- CRVS 2016
- Fundamental
- Price
- ENX $9.89
- CRVS $4.03
- Analyst Decision
- ENX
- CRVS Buy
- Analyst Count
- ENX 0
- CRVS 3
- Target Price
- ENX N/A
- CRVS $5.75
- AVG Volume (30 Days)
- ENX 25.4K
- CRVS 405.1K
- Earning Date
- ENX 01-01-0001
- CRVS 08-06-2024
- Dividend Yield
- ENX 3.94%
- CRVS N/A
- EPS Growth
- ENX N/A
- CRVS N/A
- EPS
- ENX 0.16
- CRVS N/A
- Revenue
- ENX N/A
- CRVS N/A
- Revenue This Year
- ENX N/A
- CRVS N/A
- Revenue Next Year
- ENX N/A
- CRVS N/A
- P/E Ratio
- ENX $61.00
- CRVS N/A
- Revenue Growth
- ENX N/A
- CRVS N/A
- 52 Week Low
- ENX $7.84
- CRVS $1.05
- 52 Week High
- ENX $10.07
- CRVS $4.75
- Technical
- Relative Strength Index (RSI)
- ENX 47.19
- CRVS 58.05
- Support Level
- ENX $9.86
- CRVS $3.90
- Resistance Level
- ENX $9.96
- CRVS $4.75
- Average True Range (ATR)
- ENX 0.08
- CRVS 0.30
- MACD
- ENX -0.01
- CRVS -0.08
- Stochastic Oscillator
- ENX 14.55
- CRVS 18.18
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).